C
Constance M. Yuan
Researcher at National Institutes of Health
Publications - 133
Citations - 10629
Constance M. Yuan is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Minimal residual disease & Multiple myeloma. The author has an hindex of 35, co-authored 133 publications receiving 8169 citations.
Papers
More filters
Journal ArticleDOI
In Patients With Chronic Lymphocytic Leukemia (CLL) Ibrutinib Effectively Reduces Clonal IgM Paraproteins and Serum Free Light Chains While Increasing Normal IgM, IgA Serum Levels, Suggesting a Nascent Recovery Of Humoral Immunity
Mohammed Farooqui,Jade Jones,Janet Valdez,Sabrina Martyr,Susan Soto,Maryalice Stetler-Stevenson,Constance M. Yuan,Adrian Wiestner +7 more
TL;DR: Ibrutinib effectively reduces the clonal light chain, a correlate of tumor control, while the non-clonal light chains, presumably in part reflecting normal B-cells, are low pre-treatment and increase during treatment, suggesting a beginning recovery of humoral immunity.
Journal ArticleDOI
Single Agent Ibrutinib (PCI-32765) Achieves Equally Good and Durable Responses In Chronic Lymphocytic Leukemia (CLL) Patients With and Without Deletion 17p
Mohammed Farooqui,Georg Aue,Janet Valdez,Sabrina Martyr,Jade Jones,Susan Soto,Maryalice Stetler-Stevenson,Constance M. Yuan,Diane C. Arthur,Francine Thomas,Xin Tian,Delong Liu,Irina Maric,Adrian Wiestner +13 more
TL;DR: This investigator-initiated phase II, single-center trial of ibrutinib monotherapy prospectively addressed the possible role of IbrutinIB in DEL 17p CLL irrespective of the pts’ prior treatment history.
Journal ArticleDOI
Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia
Dalia A. Salem,Drake Scott,Catharine S. McCoy,David J. Liewehr,David Venzon,Evgeny Arons,Robert J. Kreitman,Maryalice Stetler-Stevenson,Constance M. Yuan +8 more
TL;DR: Examination of CD43, CD81, CD79b, and CD200 expression in HCL and HCLv found no evidence of CD25, CD123, CD200, annexin‐A1, or BRAF V600E mutation.
Journal ArticleDOI
Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Can Render Patients with ALL Into PCR-Negative Remission and Can be an Effective Bridge to Transplant (HCT)
Haneen Shalabi,Cindy Delbrook,Maryalice Stetler-Stevenson,Constance M. Yuan,Seth M. Steinberg,Bonnie Yates,Terry J. Fry,Daniel W. Lee,Nirali N. Shah +8 more
Journal ArticleDOI
Novel CD19 expression in a peripheral T cell lymphoma: A flow cytometry case report with morphologic correlation.
TL;DR: Peripheral T‐ cell lymphomas are uncommon lymphomas that show T‐cell antigenic loss and clonal T‐cells receptor (TCR) gene rearrangement.